Abstract
BACKGROUND: Because randomized controlled trials of established pediatric asthma therapies are expensive and difficult to perform, observational studies may fill gaps in the evidence base.
OBJECTIVES: To compare the effectiveness of representative small-particle inhaled corticosteroid (ICS) with that of standard size-particle ICS for children initiating or stepping up ICS therapy for asthma (analysis 1) and to compare the effectiveness of ICS dose step-up using small-particle ICS with adding long-acting beta(2)-agonist (LABA) to the ICS (analysis 2).
METHODS: These historical matched cohort analyses drew on electronic medical records of children with asthma aged 5 to 11 years. Variables measured during 2 consecutive years (1 baseline year for confounder definition and 1 outcome year) included risk-domain asthma control (no hospital attendance for asthma, acute oral corticosteroids, or lower respiratory tract infection requiring antibiotics) and rate of severe exacerbations (asthma-related emergency, hospitalization, or oral corticosteroids).
RESULTS: In the initiation population (n = 797 in each cohort), children prescribed small-particle ICS versus standard sizeeparticle ICS experienced greater odds of asthma control (adjusted odds ratio, 1.49; 95% CI, 1.10-2.02) and lower severe exacerbation rate (adjusted rate ratio, 0.56; 95% CI, 0.35-0.88). Step-up outcomes (n = 206 in each cohort) were also significantly better for small-particle ICS, with asthma control adjusted odds ratio of 2.22 (95% CI, 1.23-4.03) and exacerbations adjusted rate ratio of 0.49 (95% CI, 0.27-0.89). The number needed to treat with small-particle ICS to achieve 1 additional child with asthma control was 17 (95% CI, 9-107) for the initiation population and 5 (95% CI, 3-78) for the step-up population. Outcomes were not significantly different for stepped-up small-particle ICS dose versus ICS/LABA combination (n = 185 in each cohort).
CONCLUSIONS: Initiating or stepping up the ICS dose with small-particle ICS rather than with standard sizeeparticle ICS is more effective and shows similar effectiveness to add-on LABA in childhood asthma. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
Original language | English |
---|---|
Pages (from-to) | 721-731 |
Number of pages | 11 |
Journal | The Journal of Allergy and Clinical Immunology: In Practice |
Volume | 3 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2015 |
Keywords
- Asthma
- Childhood
- Small-particle beclomethasone
- Fluticasone
- Inhaled corticosteroid
- Long-acting beta(2)-agonist
- Step-up therapy
- PRACTICE RESEARCH DATABASE
- METERED-DOSE INHALER
- BECLOMETHASONE DIPROPIONATE
- HFA-BECLOMETHASONE
- EXTRAFINE AEROSOL
- EPIDEMIOLOGY STROBE
- PERSISTENT ASTHMA
- CONTROLLED-TRIAL
- LUNG DEPOSITION
- DOUBLE-BLIND